- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PROKIDNEY Aktie jetzt für 0€ handeln | |||||
| 17.06. | Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel's Accelerated Approval Path | 1 | Insider Monkey | ||
| 02.06. | ProKidney beruft Kenneth Locke zum Chief Technical Officer | 2 | Investing.com Deutsch | ||
| 02.06. | ProKidney Appoints Kenneth Locke as Chief Technical Officer | 150 | GlobeNewswire (Europe) | WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease... ► Artikel lesen | |
| 18.05. | ProKidney GAAP EPS of -$0.14 beats by $0.01, revenue of $0.23M beats by $0.03M | 1 | Seeking Alpha | ||
| 15.05. | ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates | 1 | Zacks | ||
| 15.05. | PROKIDNEY CORP. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | PROKIDNEY CORP. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.05. | ProKidney Reports First Quarter 2026 Financial Results and Business Highlights | 267 | GlobeNewswire (Europe) | On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027Peer-reviewed results from the Phase... ► Artikel lesen | |
| 25.03. | ProKidney names Greg Madison as chief commercial officer | 2 | Investing.com | ||
| 25.03. | ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer | 195 | GlobeNewswire (Europe) | WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney... ► Artikel lesen | |
| 18.03. | BofA reiterates ProKidney stock Underperform rating at $1 target | 2 | Investing.com | ||
| 18.03. | BofA bestätigt "Underperform"-Rating für ProKidney mit Kursziel von 1 US-Dollar | 3 | Investing.com Deutsch | ||
| 18.03. | ProKidney GAAP EPS of -$0.52 beats by $0.18, revenue of $0.89M beats by $0.35M | 1 | Seeking Alpha | ||
| 18.03. | PROKIDNEY CORP. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 18.03. | PROKIDNEY CORP. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.03. | PROKIDNEY CORP. - 10-K, Annual Report | 2 | SEC Filings | ||
| 02.02. | PROKIDNEY CORP. - 8-K, Current Report | 3 | SEC Filings | ||
| 12.01. | PROKIDNEY CORP. - 8-K, Current Report | 3 | SEC Filings | ||
| 27.12.25 | ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright | 2 | Insider Monkey | ||
| 10.11.25 | ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates | 308 | GlobeNewswire (Europe) | Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 32,610 | +1,73 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen vor Zahlen zum zweiten Quartal auf "Buy" belassen. Diese dürften sich im Rahmen der eigenen Vorgaben des Diagnostikspezialisten... ► Artikel lesen | |
| VALNEVA | 2,314 | -0,09 % | Valneva zieht durch: Analysten sehen massives Kurspotenzial - Die Fakten auf einen Blick | ||
| NOVAVAX | 8,070 | +2,54 % | Novavax-Aktionäre billigen auf Hauptversammlung wichtige Anträge | ||
| HEIDELBERG PHARMA | 2,670 | +2,30 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma berichtet über die Ergebnisse der ordentlichen Hauptversammlung 2026 | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Hauptversammlung
Heidelberg Pharma berichtet über die Ergebnisse der ordentlichen Hauptversammlung 2026
23.06.2026 / 15:39... ► Artikel lesen | |
| NANOREPRO | 2,130 | +9,51 % | EQS-News: NanoRepro AG: Lizenzpartnerschaft mit der FiberSense AG wird in eine strategische Eigenkapitalbeteiligung überführt - CE-Kennzeichnung erteilt, Positionierung im Milliardenmarkt der kontinuierlichen G | EQS-News: NanoRepro AG
/ Schlagwort(e): Strategische Unternehmensentscheidung/Beteiligung/Unternehmensbeteiligung
NanoRepro AG: Lizenzpartnerschaft mit der FiberSense AG wird... ► Artikel lesen | |
| VIVOSIM LABS | 1,120 | -0,88 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| OCUGEN | 1,208 | +6,53 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,966 | -1,08 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,222 | -3,48 % | BioNxt Solutions Inc.: BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption | Not for distribution to U.S. newswire services or for dissemination in the United States. VANCOUVER, BC / ACCESS Newswire / June 23, 2026 / BioNxt Solutions Inc. (CSNX:BNXT)(OTCQB:BNXTF)(FSE:BXT) (the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,050 | +6,00 % | Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy? | ||
| INFLARX | 1,671 | +0,72 % | Was Insider bei InflaRx NV noch vor Börsenschluss bereits wissen: Steht hier der Beginn einer neuen Rally? - Handeln Sie, bevor es zu spät ist | ||
| INTELLIA THERAPEUTICS | 13,560 | -1,74 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| TEMPUS AI | 42,485 | +1,40 % | Should You Retain Tempus AI Stock In Your Portfolio Now? | ||
| EDITAS MEDICINE | 2,400 | -1,64 % | Editas Medicine, Inc. - 8-K, Current Report | ||
| GENMAB | 226,80 | +1,43 % | Genmab Presents Promising Epcoritamab Data In Elderly DLBCL Patients | WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) reported positive findings from two clinical studies evaluating epcoritamab in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)... ► Artikel lesen |
PROKIDNEY CORP gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,790 Euro und damit -1,65 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROKIDNEY CORP finden Sie auf Wallstreet Online.